Effects of a short-acting β1 receptor antagonist landiolol on hemodynamics and tissue injury markers in patients with subarachnoid hemorrhage undergoing intracranial aneurysm surgery

Journal of Neurosurgical Anesthesiology

Volumn 22, Issue 3, 2010, Pages 230-239

  Kawaguchi, Masahiko ^a   Utada, Kouji ^b   Yoshitani, Kenji ^c   Uchino, Hiroyuki ^d   Takeda, Yoshimasa ^e   Masui, Kenichi ^f   Sakabe, Takefumi ^b  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^f NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

1 receptor antagonist; landiolol; S 100 ; subarachnoid hemorrhage; sympathetic nervous system

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BARBITURIC ACID DERIVATIVE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DILTIAZEM; FENTANYL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LANDIOLOL; METHOXAMINE; MIDAZOLAM; PHENYLEPHRINE; PROPOFOL; PROTEIN S100B; SHORT ACTING DRUG; TROPONIN T; VECURONIUM;

ADULT; ANEURYSM SURGERY; ARTICLE; BLOOD PRESSURE; BOLUS INJECTION; BRADYCARDIA; BRAIN DAMAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; ECG ABNORMALITY; FEMALE; HEART INJURY; HEART RATE; HEMODYNAMICS; HUMAN; HYPOTENSION; INCIDENCE; INTRACRANIAL ANEURYSM; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUBARACHNOID HEMORRHAGE; SURGICAL PATIENT; TACHYCARDIA; TISSUE INJURY;

ADRENERGIC BETA-ANTAGONISTS; AGED; BIOLOGICAL MARKERS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BRAIN; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HEART RATE; HEMODYNAMICS; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; MORPHOLINES; NERVE GROWTH FACTORS; NEUROSURGICAL PROCEDURES; RECEPTORS, ADRENERGIC, BETA-1; S100 PROTEINS; SUBARACHNOID HEMORRHAGE; UREA;

EID: 77954086941     PISSN: 08984921     EISSN: None     Source Type: Journal    
DOI: 10.1097/ANA.0b013e3181d0c2e4     Document Type: Article

References (30)

1. Priebe HJ. Aneurysmal subarachnoid haemorrhage and the anaesthetist. Br J Anaesth. 2007;99:102-118.
2. Coghlan LA, Hindman BJ, Bayman EO, et al. Independent associations between electrocardiographic abnormalities and outcomes in patients with aneurismal subarachnoid hemorrhage. Findings from the Intraoperative Hypothermia Aneurysm Surgery Trial. Stroke. 2009;40:412-418.
3. Tung P, Kopelnik A, Banki N, et al. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke. 2004;35:548-553.
4. Tung PP, Olmsted E, Kopelnik A, et al. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. Stroke. 2005;36:1567-1569.
5. Kato H, Kawaguchi M, Inoue S, et al. The effects of b-adrenoceptor antagonists on proinflammatory cytokine concentrations after subarachnoid hemorrhage in rats. Anesth Analg. 2009;108:288-295.
6. Mathiesen T, Andersson B, Loftenius A, et al. Increased interleukin-6 levels in cerebrospinal fluid following subarachnoid hemorrhage. J Neurosurg. 1993;78:562-567.
7. Osuka K, Suzuki Y, Tanazawa T, et al. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta Neurochir (Wien). 1998;140:953-1951
8. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neuosurg Psychiatry. 2001;70:534-537.
9. Naredi S, Lambert G, Friberg P, et al. Sympathetic activation and inflammatory response in patients with subarachnoid haemorrhage. Intensive Care Med. 2006;32:1955-1961.
10. Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting betablocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40:1462-1469.
11. Harasawa R, Hayashi Y, Iwasaki M, et al. Bolus administration of landiolol, a short-acting, selective beta1-blocker, to treat tachycardia during anesthesia: a dose-dependent study. J Cardiothorac Vasc Anesth. 2006;20:793-795.
12. Yamazaki A, Kinoshita H, Shimogai M, et al. Landiolol attenuates tachycardia in response to endotracheal intubation without affecting blood pressure. Can J Anaesth. 2005;52:254-257.
13. Yoshida Y, Terajima K, Sato C, et al. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008;22:64-69.
14. Goto K, Shingu C, Miyamoto S, et al. The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. J Clin Anesth. 2007;19:523-529.
15. Hunt WE, Kosnik EJ. Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg. 1974;21:79-89.
16. Jennett B, Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet. 1975;1:480-484.
17. Shafer S, Struys MM. Mixed effect modeling in analgesia trials. Anesth Analg. 2008;107:9-10.
18. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839-1847.
19. Brouwers PJ, Wijdicks EF, Hasan D, et al. Serial electrocardiographic recording in aneurysmal subarachnoid hemorrhage. Stroke. 1989;20:1162-1167. (Pubitemid 19226909)
20. Zaroff J, Rordorf G, Newll J, et al. Cardiac outcome in patients with subarachnoid hemorrhage and electrocardiographic abnormalities. Neurosurgery. 1999;44:34-39.
21. Sommargren CE, Zaro. JG, Banki N, et al. Electrocardiographic repolarization abnormalities in subarachnoid hemorrhage. J Electrocardiol. 2002;35(suppl):257-262.
22. Haimoto H, Hosoda S, Kato K. Di.erential distribution of immunoreactive S100-a and S100-bproteins in normal nonnervous human tissues. Lab Invest. 1987;57:489-498.
23. Sanchez-Pena P, Pereira AR, Sourour NA, et al. S100b as an additional prognostic maker in subarachnoid aneurismal hemorrhage. Crit Care Med. 2008;36:2267-2273.
24. Weiss N, Sanchez-Peña P, Roche S, et al. Prognosis value of plasma S100B protein levels after subarachnoid aneurismal hemorrhage. Anesthesiology. 2006;104:648-666.
25. Hardemark HG, Almqvist O, Johansson T, et al. S-100 protein in cerebrospinal .uid after aneurismal subarachnoid haemorrhage: relation to functional outcome, late CT and SPECT changes, and signs of higher cortical dysfunction. Acta Neurochir. 1989;99:135-144.
26. Persson L, Hardemark HG, Gustafsson J, et al. S-100 protein in cerebrospinal .uid of patients with subarachnoid haemorrhage: a potential marker of brain damage. Acta Neurochir. 1988;93: 116-122.
27. Cheng WE, Shih CM, Hang LW, et al. Urinary biomarker of oxidative stress correlating with outcome in critically septic patients. Intensive Care Med. 2007;33:1187-1190.
28. Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology. 2005;64:1081-1083.
29. Wu LL, Chiou CC, Chang PY, et al. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta. 2004;339:1-9.
30. Mizukoshi G, Katsura K, Katayama Y. Urinary 8-hydroxy-20- deoxyguanosine and serum S100beta in acute cardioembolic stroke patients. Neurol Res. 2005;27:644-646.